Patent application number | Description | Published |
20090162372 | FIBRONECTIN ED-B ANTIBODIES, CONJUGATES THEREOF, AND METHODS OF USE - The present invention provides anti-ED-B antibodies, antibody fragments, and antibody mimetics and such antibodies conjugated to a partner molecule, wherein the antibody or the antibody-partner molecule conjugate provides a therapeutic effect regardless of whether the ED-B-antibody or ED-B-conjugate complex is internalized within a targeted cell. | 06-25-2009 |
20100150950 | HUMAN ANTIBODIES THAT BIND CD70 AND USES THEREOF - The present disclosure provides isolated monoclonal antibodies that specifically bind to CD70 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human CD70. In certain embodiments, the antibodies are capable of being internalized into CD70-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD70, as well as methods for treating cancers, such as renal cancer and lymphomas, using an anti-CD7Q antibody of this disclosure. | 06-17-2010 |
20110020329 | CONJUGATES OF ANTI-RG-1 ANTIBODIES - Anti-RG-1 antibodies, antibody fragments, or antibody mimetics conjugated to partner molecules, such as drugs, radioisotopes, and cytotoxins, wherein the partner molecule exerts its effect regardless of whether the RG-1 bound conjugate is internalized within a targeted cell, are useful for treating cancers. | 01-27-2011 |
20110085970 | ANTI-B7H4 MONOCLONAL ANTIBODY-DRUG CONJUGATE AND METHODS OF USE - The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to B7H4 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided, immunoconjugates, including antibody-drug conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for treating cancer. | 04-14-2011 |
20110262448 | HUMAN ANTIBODIES THAT BIND MESOTHELIN, AND USES THEREOF - The present disclosure provides isolated monoclonal antibodies that specifically bind to mesothelin with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human mesothelin. In certain embodiments, the antibodies are capable of internalizing into mesothelin-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. The invention further provides anti-mesothelin antibodies that can inhibit the binding of mesothelin to the ovarian cancer antigen CA125. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting mesothelin, as well as methods for treating cancers, such as mesotheliomas, pancreatic cancers and ovarian cancers, using an anti-mesothelin antibody of this disclosure. | 10-27-2011 |
20130028904 | HUMAN ANTIBODIES THAT BIND MESOTHELIN, AND USES THEREOF - The present disclosure provides isolated monoclonal antibodies that specifically bind to mesothelin with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human mesothelin. In certain embodiments, the antibodies are capable of internalizing into mesothelin-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. The invention further provides anti-mesothelin antibodies that can inhibit the binding of mesothelin to the ovarian cancer antigen CA125. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting mesothelin, as well as methods for treating cancers, such as mesotheliomas, pancreatic cancers and ovarian cancers, using an anti-mesothelin antibody of this disclosure. | 01-31-2013 |
20130028905 | HUMAN ANTIBODIES THAT BIND MESOTHELIN, AND USES THEREOF - The present disclosure provides isolated monoclonal antibodies that specifically bind to mesothelin with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human mesothelin. In certain embodiments, the antibodies are capable of internalizing into mesothelin-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. The invention further provides anti-mesothelin antibodies that can inhibit the binding of mesothelin to the ovarian cancer antigen CA125. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting mesothelin, as well as methods for treating cancers, such as mesotheliomas, pancreatic cancers and ovarian cancers, using an anti-mesothelin antibody of this disclosure. | 01-31-2013 |
20130028906 | HUMAN ANTIBODIES THAT BIND MESOTHELIN, AND USES THEREOF - The present disclosure provides isolated monoclonal antibodies that specifically bind to mesothelin with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human mesothelin. In certain embodiments, the antibodies are capable of internalizing into mesothelin-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. The invention further provides anti-mesothelin antibodies that can inhibit the binding of mesothelin to the ovarian cancer antigen CA125. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting mesothelin, as well as methods for treating cancers, such as mesotheliomas, pancreatic cancers and ovarian cancers, using an anti-mesothelin antibody of this disclosure. | 01-31-2013 |
20130190481 | HUMAN ANTIBODIES THAT BIND MESOTHELIN, AND USES THEREOF - The present disclosure provides isolated monoclonal antibodies that specifically bind to mesothelin with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human mesothelin. In certain embodiments, the antibodies are capable of internalizing into mesothelin-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. The invention further provides anti-mesothelin antibodies that can inhibit the binding of mesothelin to the ovarian cancer antigen CA125. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting mesothelin, as well as methods for treating cancers, such as mesotheliomas, pancreatic cancers and ovarian cancers, using an anti-mesothelin antibody of this disclosure. | 07-25-2013 |
Patent application number | Description | Published |
20080312146 | METH1 and METH2 Polynucleotides and Polypeptides - The present invention relates to novel anti-angiogenic proteins, related to thrombospondin. More specifically, isolated nucleic acid molecules are provided encoding human METH1 and METH2. METH1 and METH2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for the prognosis of cancer and therapeutic methods for treating individuals in need of an increased amount of METH1 or METH2. Also provided are methods for inhibiting angiogenesis using METH1 or METH2. | 12-18-2008 |
20080318835 | Novel Integrin Ligand ITGL-TSP - ITGL-TSP polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing ITGL-TSP polypeptides and polynucleotides in the design of protocols for the treatment of, angiogenic diseases (cancer, cancer metastasis, chronic inflammatory disorders, rheumatoid arthritis, atherosclerosis, macular degeneration, diabetic retmopathy), restenosis, Alzheimer's, disease and tissue remodeling, among others, and diagnostic assays for such conditions. | 12-25-2008 |
Patent application number | Description | Published |
20080226644 | Novel cancer associated protein - The present invention relates to a novel polypeptide (BCMP 101) compositions comprising the polypeptide, including vaccines, and antibodies that are immunospecific for the polypeptide. The use of the polypeptide in the diagnosis, prophylaxis and treatment of cancer, in particular breast cancer is also provided. | 09-18-2008 |
20090246201 | Substances - The present invention provides a homologue to heparanase which is present in three splice variants. | 10-01-2009 |
20090258019 | Diagnosis of carcinoma using RAIG1 polypeptides - The present invention relates to the new uses of a polypeptide (retinoic acid-inducible gene 1; RAIG1, also known as hypothetical protein FLJ10899 or retinoic acid induced 3) compositions comprising the polypeptide, including vaccines, antibodies that are immunospecific for the polypeptide and agents which interact with or modulate the expression or activity of the polypeptide or the expression of the nucleic acid which encodes the polypeptide. The use of the polypeptide in the diagnosis, screening and treatment of carcinoma, e.g. breast cancer, pancreatic cancer, lung cancer, liver cancer, ovarian cancer, colon cancer and/or osteosarcoma, is also provided. | 10-15-2009 |
20100015152 | Diagnostic and therapeutic methods - The present invention provides the use of a protein found in breast, prostate, pancreatic and colon cancer cell membranes, known as BCMP 7, in the diagnosis, screening, treatment and prophylaxis of breast, prostate, pancreatic and/or colon cancer, as well as compositions comprising BCMP 7, including vaccines and antibodies that are immunospecific for BCMP 7. | 01-21-2010 |
20110150877 | EPHRIN-B RECEPTOR PROTEIN INVOLVED IN CARCINOMA - The present invention provides a polypeptide (CCMP-1) of use in the diagnosis, screening, treatment and prophylaxis of carcinoma. Also provided are compositions comprising the protein, vaccines and antibodies that are immunospecific for the protein. | 06-23-2011 |
Patent application number | Description | Published |
20100285017 | MATRIPTASE PROTEIN AND USES THEREOF - The present invention provides methods and compositions for treatment, screening, diagnosis, prognosis and therapy of breast cancer, colorectal cancer, esophageal cancer, gastric cancer, prostate cancer and uterine cancer, for monitoring the effectiveness of breast cancer, colorectal cancer, esophageal cancer, gastric cancer, prostate cancer and uterine cancer treatment, and for drug development. | 11-11-2010 |
20110195026 | PROTEIN - The present invention provides methods and compositions for the treatment of and for screening, diagnosis and prognosis of colorectal cancer, for monitoring the effectiveness of colorectal cancer treatment, and for drug development. | 08-11-2011 |
20120114672 | Antibodies Specific to Cadherin-17 - The present disclosure provides antibodies, including isolated monoclonal antibodies, which specifically bind to Cadherin-17 with high affinity. Nucleic acid molecules encoding Cadherin-17 antibodies, expression vectors, host cells and methods for expressing the Cadherin-17 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the Cadherin-17 antibodies are also provided. Methods for detecting Cadherin-17, as well as methods for treating various cancers, including colorectal cancer, are disclosed. | 05-10-2012 |
20120231004 | ANTIBODIES - The present disclosure provides antibodies, including isolated monoclonal antibodies, which specifically bind to the Ephrin type-A receptor 10 with high affinity. Nucleic acid molecules encoding the Ephrin type-A receptor 10 antibodies, expression vectors, host cells and methods for expressing the Ephrin type-A receptor 10 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the Ephrin type-A receptor 10 antibodies are also provided. Methods for detecting the Ephrin type-A receptor 10, as well as methods for treating various cancers, including bladder cancer, breast cancer, colorectal cancer, head and neck cancer, kidney cancer, lung cancer, uterine cancer and pancreatic cancer are disclosed. | 09-13-2012 |
20120282177 | ROR1 as Therapeutic and Diagnostic Target - The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of cancer including bladder cancer, breast cancer, colorectal cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, skin cancer and thyroid cancer. | 11-08-2012 |
20130251723 | ANTI-ROR1 ANTIBODIES - The invention provides antibodies which bind to the extracellular domain of the Tyrosine-protein kinase transmembrane receptor ROR1. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided. The antibodies may be used for the treatment of cancer, including non-small cell lung carcinoma, B-cell chronic lymphocytic leukemia and colon cancer. | 09-26-2013 |
20130273068 | ANTIBODIES - The invention provides antibodies which bind to the ADP-ribosyl cyclase 2. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided. The antibodies may be used for the treatment of human cancers, including acute myeloid leukemia (AML), B-cell chronic lymphocytic leukemia, breast cancer, colorectal cancer, kidney cancer, head and neck cancer, lung cancer, ovarian cancer and pancreatic cancer and human inflammatory diseases, including asthma, gout, crohns, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, diabetes and atherosclerotic. | 10-17-2013 |
20140024048 | PROTEIN - The present invention provides methods and compositions for the treatment of and for screening, diagnosis and prognosis of colorectal cancer, for monitoring the effectiveness of colorectal cancer treatment, and for drug development. | 01-23-2014 |
Patent application number | Description | Published |
20120027782 | MONOCLONAL ANTIBODY PARTNER MOLECULE CONJUGATES DIRECTED TO PROTEIN TYROSINE KINASE 7 (PTK7) - The present disclosure relates to antibody-partner molecule conjugates directed to PTK7. Also described are methods for treating or preventing a disease characterized by growth of tumor cells expressing PTK7 using the antibody-partner molecule conjugates. | 02-02-2012 |
20120093826 | FULLY HUMAN ANTIBODIES SPECIFIC TO CADM1 - The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, more particularly engineered antibodies resulting in increased binding to Fc receptors and/or increased potency for ADCC or immunoconjugates, which specifically bind to CADM1 with high affinity. Nucleic acid molecules encoding CADM1 antibodies, expression vectors, host cells and methods for expressing the CADM1 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the CADM1 antibodies are also provided. Methods for detecting CADM1, as well as methods for treating various cancers, including lung cancer and pancreatic cancer, are disclosed. | 04-19-2012 |
20120207764 | HUMAN MONOCLONAL ANTIBODIES TO PROTEIN TYROSINE KINASE 7 (PTK7) AND METHODS FOR USING ANTI-PTK7 ANTIBODIES - The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PTK7 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PTK7, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PTK7 antibodies. | 08-16-2012 |
20120219557 | HUMAN MONOCLONAL ANTIBODIES TO PROTEIN TYROSINE KINASE 7 (PTK7) AND METHODS FOR USING ANTI-PTK7 ANTIBODIES - The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PTK7 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PTK7, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PTK7 antibodies. | 08-30-2012 |
20130156788 | FULLY HUMAN ANTIBODIES SPECIFIC TO CADM1 - The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, more particularly engineered antibodies resulting in increased binding to Fc receptors and/or increased potency for ADCC or immunoconjugates, which specifically bind to CADM1 with high affinity. Nucleic acid molecules encoding CADM1 antibodies, expression vectors, host cells and methods for expressing the CADM1 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the CADM1 antibodies are also provided. Methods for detecting CADM1, as well as methods for treating various cancers, including lung cancer and pancreatic cancer, are disclosed. | 06-20-2013 |
20130259878 | ANTIBODIES - The present disclosure provides antibodies, including isolated monoclonal antibodies, which specifically bind to CDH17 with high affinity. Nucleic acid molecules encoding CDH17 antibodies, expression vectors, host cells and methods for expressing CDH17 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the CDH17 antibodies are also provided. Methods for detecting CD-H17, as well as methods for treating carious cancers, including gastric cancer, pancreatic cancer, colon cancer and colorectal cancer, are disclosed. | 10-03-2013 |
20140186892 | MONOCLONAL ANTIBODIES AGAINST GLYPICAN-3 - The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Glypican-3 with high affinity. Nucleic acid molecules encoding Glypican-3 antibodies, expression vectors, host cells and methods for expressing the Glypican-3 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the Glypican-3 antibodies are also provided. Methods for detecting Glypican-3, as well as methods for treating various Glypican-3-related conditions, including hepatocellular cancer, are disclosed. | 07-03-2014 |